Lymphoma Clinical Trial
— GLOBRYTEOfficial title:
A Phase III, Open-Label, Multicenter Randomized Study Evaluating Glofitamab as a Single Agent Versus Investigator's Choice in Patients With Relapsed/Refractory Mantle Cell Lymphoma
The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).
Status | Recruiting |
Enrollment | 182 |
Est. completion date | December 31, 2026 |
Est. primary completion date | February 2, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Life expectancy at least 12 weeks - Histologically-confirmed MCL, with documentation of either overexpression of cyclin D1 or the presence of t(11:14) - Relapsed (disease progression after the last treatment regimen) or refractory (failure to achieve a partial or complete response from the last treatment regimen) disease - At least 1 line of prior systemic therapy including a BTK inhibitor and additional systemic therapy option - Confirmed availability of tumor tissue, unless deemed unsafe per investigator assessment - At least one bi-dimensionally measurable (defined as at least 1.5 cm) nodal lesion, or one bi-dimensionally measurable (at least 1 cm) extranodal lesion, as measured on CT scan - Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 - Negative HIV test at screening - Adequate hematological function Exclusion Criteria: - Pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 3 months after the final dose of tocilizumab, 2 months after the final dose of glofitamab, whichever is longer - Leukemic, non-nodal MCL - History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies (or recombinant antibody-related fusion proteins) or known sensitivity or allergy to murine products - Contraindication to obinutuzumab or rituximab, and either bendamustine or lenalidomide - Prior treatment with glofitamab or other bispecific antibodies targeting both CD20 and CD3 - Prior treatment with CAR-T cell therapy - Treatment with systemic therapy or BTK inhibitors, or any investigational agent for the purposes of treating cancer within 2 weeks or 5 half-lives (whichever is shorter) prior to first study treatment - Primary or secondary CNS lymphoma at the time of recruitment or history of CNS lymphoma - Current or history of CNS disease, such as stroke, epilepisy, CNS vasculitis, or neurodegenerative disease - History of other malignancy that could affect compliance with the protocol or interpretation of results - Significant or extensive cardiovascular disease - Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection at study enrollment or any major episode of infection within 4 weeks prior to the first study treatment - Suspected or latent tuberculosis - Positive test for hepatitis B virus (HBV) or hepatitis C virus (HCV) - Known or suspected chronic active Epstein-Barr viral infection (EBV) - Known or suspected history of hemophagocytic lymphohistiocytosis (HLH) - Known history of progressive multifocal leukoencephalopathy (PML) - Adverse events from prior anti-cancer therapy that have not resolved to Grade 1 or better - Administration of a live, attenuated vaccine within 4 weeks before first study treatment administration or anticipation that such a live, attenuated vaccine will be required during the study - Prior solid organ transplantation or allogenic stem cell transplant - Eligibility for stem cell transplantation (SCT) - Active autoimmune disease requiring treatment - Prior treatment with systemic immunosuppressive medications within 2 weeks or five half-lives (whichever is shorter) prior to the first dose of study treatment - Corticosteroid therapy within 2 weeks prior to first dose of study treatment - Recent major surgery (within 4 weeks before the first study treatment) other than for diagnosis - Clinically significant history of cirrhotic liver disease |
Country | Name | City | State |
---|---|---|---|
Australia | Royal Adelaide Hospital; Haematology Clinical Trials | Adelaide | South Australia |
Australia | Epworth Hospital | Richmond | Victoria |
Australia | Calvary Mater Newcastle; Medical Oncology | Waratah | New South Wales |
Brazil | ICTR Curitiba | Curitiba | PR |
Brazil | Hospital Mae de Deus | Porto Alegre | RS |
Brazil | Americas Medical City | Rio de Janeiro | RJ |
Brazil | Hospital A. C. Camargo; Oncologia | Sao Paulo | SP |
Brazil | Hospital Alemao Oswaldo Cruz | Sao Paulo | SP |
Brazil | Hospital Paulistano | Sao Paulo | SP |
Brazil | Instituto D'Or Pesquisa e Ensino | Sao Paulo | SP |
Brazil | Beneficencia Portuguesa de Sao Paulo | São Paulo | SP |
Canada | Victoria Hospital - London Health Sciences Centre | London | Ontario |
Canada | The Ottawa Hospital - General Campus | Ottawa | Ontario |
China | Beijing Tong Ren Hospital, Capital Medical University | Beijing | |
China | The First Hospital of Jilin University | Changchun City | |
China | West China Hospital of Sichuan University | Chengdu City | |
China | Chongqing Cancer Hospital | Chongqing | |
China | Fujian Provincial Cancer Hospital | Fuzhou City | |
China | Sun yat-sen University Cancer Center; Internal Medicine of Oncology | Guangzhou | |
China | Guangxi Cancer Hospital of Guangxi Medical University | Nanning City | |
China | Fudan University Shanghai Cancer Center; Medical Oncology | Shanghai City | |
China | The First Affiliated Hospital of China Medical University | Shenyang City | |
China | The First Affiliated Hospital of Wenzhou Medical University | Wenzhou City | |
China | The First Affiliated Hospital of Zhengzhou University; Branch Hospital in NEW ZHENGDONG District | Zhengzhou | |
China | Henan Cancer Hospital; Hematology department | Zhengzhou City | |
France | Hopital Claude Huriez; Hematologie | Lille | |
France | Hopital Saint Eloi; Hematologie Oncologie Medicale | Montpellier | |
France | CHU NANTES - Hôtel Dieu; Service d'Hematologie Clinique | Nantes | |
France | INSTITUT CURIE_SITE PARIS - Service d'Oncologie Médicale. | St Cloud | |
Italy | SC Ematologia, AO SS. Antonio e Biagio e C. Arrigo | Alessandria | Piemonte |
Italy | Humanitas Gavazzeni;U.O. Oncologia Medica | Bergamo | Lombardia |
Italy | Irccs Istituto Europeo Di Oncologia (IEO); Emato-Oncologia | Milano | Lombardia |
Italy | A.O. Città della Salute e della Scienza D - Osp. S. Giov. Battista Molinette; Ematologia I | Torino | Piemonte |
Korea, Republic of | Chungnam National University Hospital | Daejeon | |
Korea, Republic of | Asan Medical Center | Seoul | |
Korea, Republic of | Samsung Medical Center | Seoul | |
Korea, Republic of | Seoul National University Hospital | Seoul | |
Korea, Republic of | Severance Hospital, Yonsei University Health System | Seoul | |
Spain | Hospital Clinic de Barcelona | Barcelona | |
Spain | Hospital Universitari Vall d'Hebron; Servicio de Hematologia | Barcelona | |
Spain | Hospital Universitario Puerta del Mar; Servicio de Hematologia | Cádiz | Cadiz |
Spain | Complejo Hospitalario Universitario A Coruña (CHUAC); Servicio de Hematologia | La Coruna | LA Coruña |
Spain | Hospital General Universitario J.M Morales Meseguer; Servicio de Hematología | Murcia | |
Sweden | Skånes University Hospital, Skånes Department of Onclology | Lund | |
Sweden | Akademiska sjukhuset, Onkologkliniken | Uppsala | |
Taiwan | National Taiwan Universtiy Hospital; Division of Hematology | Taipei | |
Taiwan | Chang Gung Medical Foundation - Linkou; Division of Hematology- Oncology | Taoyuan | |
United Kingdom | Oxford Churchill Hospital; Cancer and Haematology Centre,Level 2 | Oxford | |
United Kingdom | Derriford Hospital; Haematology | Plymouth | |
United States | St. Luke's Hospital | Chesterfield | Missouri |
United States | City of Hope Cancer Center | Duarte | California |
United States | Avera Cancer Institute | Sioux Falls | South Dakota |
Lead Sponsor | Collaborator |
---|---|
Hoffmann-La Roche |
United States, Australia, Brazil, Canada, China, France, Italy, Korea, Republic of, Spain, Sweden, Taiwan, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression-free survival (PFS) | From randomization to the first occurrence of disease progression or death from any cause (up to approximately 24 months) | ||
Secondary | Complete response (CR) rate | Up to approximately 24 months | ||
Secondary | Objective response rate (ORR) | Up to approximately 24 months | ||
Secondary | Overall survival (OS) | From randomization to death from any cause (up to approximately 24 months) | ||
Secondary | Time to deterioration in physical functioning/fatigue | From randomization to a 10-point decrease in physical functioning/10-point increase in fatigue compared to baseline (up to approximately 24 months) | ||
Secondary | Investigator-assessed PFS | From randomization to disease progression or death from any cause (up to approximately 24 months) | ||
Secondary | Investigator-assessed CR rate | Up to approximately 24 months | ||
Secondary | Investigator-assessed ORR | Up to approximately 24 months | ||
Secondary | Duration of Complete Response (DOCR) | From the initial occurrence of a documented CR until documented disease progression or death due to any cause, whichever occurs first (up to approximately 24 months) | ||
Secondary | Duration of Response (DOR) | From the initial occurrence of a documented CR until documented disease progression or death due to any cause, whichever occurs first (up to approximately 24 months) | ||
Secondary | Proportion of participants reporting each response option for item GP5 from the Functional Assessment of Cancer Therapy - General (FACT-G) subscale | Up to approximately 24 months | ||
Secondary | Time to deterioration in lymphoma symptoms | From randomization to the first documentation of a 3-point or more decrease in score as assessed by the FACT-Lym lymphoma subscale (LymS) questionnaire (up to approximately 24 months) | ||
Secondary | Proportion of participants experiencing a clinically meaningful improvement (3-point or more increase) in lymphoma symptoms as assessed through use of the FACT-Lym LymS | Up to approximately 24 months | ||
Secondary | Change from baseline in physical functioning and fatigue at each cycle as assessed by the European Organization for Research and Treatment (EORTC) core Quality of Life Questionnaire (QLQ-C30) | The EORTC QLQ-C30 consists of 30 questions assessing five aspects of participant functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), global health status and quality of life (QoL), and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The functioning and symptoms items are scored on a 4-point scale that ranges from "not at all" to "very much," and the global health status and QoL items are scored on a 7-point scale that ranges from "very poor" to "excellent." | Up to approximately 24 months | |
Secondary | Change from baseline in lymphoma symptoms at each cycle as assessed by the FACT-Lym LymS | Up to approximately 24 months | ||
Secondary | Serum concentration of glofitamab | Up to approximately 24 months | ||
Secondary | Incidence of anti-drug antibodies (ADAs) | Up to approximately 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540340 -
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
|
Phase 1 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT00001512 -
Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Completed |
NCT01410630 -
FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
|
||
Active, not recruiting |
NCT04270266 -
Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT01949883 -
A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma
|
Phase 1 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Recruiting |
NCT05019976 -
Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma
|
N/A | |
Completed |
NCT04434937 -
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)
|
Phase 2 | |
Completed |
NCT01855750 -
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
|
Phase 3 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT00775268 -
18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03936465 -
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
|
Phase 1 |